Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancerKenichi Sugihara, Toshiaki Watanabe, Kei Muro et al.|International Journal of Clinical Oncology|2017Cited by 2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancerYojiro Hashiguchi, Kei Muro, Yutaka Saitō et al.|International Journal of Clinical Oncology|2019Cited by 2k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Atsushi Ohtsu, Charles S. Fuchs et al.|The Lancet|2018Cited by 1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A. Shah, Kei Muro et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859